JOEL S. MARCUS - 02 Aug 2022 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role
Director
Signature
/s/ Shoshana Shendelman, as attorney-in-fact
Issuer symbol
APLT
Transactions as of
02 Aug 2022
Net transactions value
$0
Form type
4
Filing time
04 Aug 2022, 20:39:02 UTC
Previous filing
23 Jun 2022
Next filing
12 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -16,500 -100% 0 02 Aug 2022 Common Stock 16,500 $1.22 Direct F1, F2
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +16,500 16,500 02 Aug 2022 Common Stock 16,500 $1.05 Direct F1, F2
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -16,500 -100% 0 02 Aug 2022 Common Stock 16,500 $19.70 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +16,500 16,500 02 Aug 2022 Common Stock 16,500 $1.05 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -10,230 -100% 0 02 Aug 2022 Common Stock 10,230 $44.02 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +10,230 10,230 02 Aug 2022 Common Stock 10,230 $1.05 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -7,389 -100% 0 02 Aug 2022 Common Stock 7,389 $10.00 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +7,389 7,389 02 Aug 2022 Common Stock 7,389 $1.05 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.
F2 Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
F3 These Options are fully vested.